MARATTO

article · Zagazig University Medical Journal

Brief Overview about Inherited Rare coagulation disorders

Abstract

Background: Numerous rare congenital bleeding disorders include fibrinogen and prothrombin deficiency as well as factor (V, VII, VIII, XI, X, and XIII) deficiency. In the general population, the severe variants of these illnesses are hereditary and possess a frequency that falls somewhere between one in every two million for factor XIII and one in per half a million for factor VII. Patients who have rare congenital bleeding disorders may exhibit a broad range of symptoms, from relatively mild subcutaneous bleeding to potentially life-threatening hemorrhages for example in the central nervous system. The majority of treatment for these disorders when specific plasma-derived or recombinant products are available is to replace the missing factor. Diagnosing and treating rare congenital bleeding disorders can be challenging due to the wide variety of symptoms they manifest in patients. Patients with rare inherited bleeding diseases must be closely monitored at specialized hemophilia treatment centers once they are diagnosed, due to the unique difficulty of their therapy. More research is required to improve the worldwide care for individuals with rare inherited bleeding diseases, despite the fact that a lot has been learned about their frequency, symptoms, and genetic characteristics in the past ten years. We aimed at this review to give a brief overview about Inherited Bleeding Disorders.

Research topics

  • Hemophilia Treatment and Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/zumj.2024.297107.3440

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.